Vilanterol
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09082 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | obstructive lung disease | KG + DL |
| 2 | interstitial emphysema | KG + DL |
| 3 | compensatory emphysema | KG + DL |
| 4 | hyperlucent lung | KG + DL |
| 5 | tracheal stenosis | KG + DL |
| 6 | bronchial neoplasm (disease) | KG + DL |
| 7 | congenital lobar emphysema | KG + DL |
| 8 | respiratory malformation | KG + DL |
| 9 | tracheal calcification | KG + DL |
| 10 | laryngotracheitis | KG + DL |
| 11 | Rienhoff syndrome | KG + DL |
| 12 | susceptibility to respiratory infections associated with CD8alpha chain mutation | KG + DL |
| 13 | Laubry-Pezzi syndrome | KG + DL |
| 14 | tracheal disease | KG + DL |
| 15 | genetic syndromic Pierre Robin syndrome | KG + DL |
| 16 | interventricular septum aneurysm | KG + DL |
| 17 | pulmonary valve disease | KG + DL |
| 18 | supravalvular aortic stenosis (disease) | KG + DL |
| 19 | mitral valve disease | KG + DL |
| 20 | Pierre Robin syndrome associated with a chromosomal anomaly | KG + DL |
| 21 | partial deletion of the long arm of chromosome 7 | KG + DL |
| 22 | orofacial clefting syndrome | KG + DL |
| 23 | disorder of fucoglycosan synthesis | KG + DL |
| 24 | partial deletion of the long arm of chromosome 22 | KG + DL |
| 25 | Winchester syndrome | KG + DL |
| 26 | Jeune syndrome situs inversus | KG + DL |
| 27 | heart disease | KG + DL |
| 28 | depersonalization disorder | KG + DL |
| 29 | indolent plasma cell myeloma | KG + DL |
| 30 | heart conduction disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.